Prevalence and burden of pediatric-onset systemic lupus erythematosus

Nature Reviews Rheumatology

Volumn 6, Issue 9, 2010, Pages 538-546

  Kamphuis, Sylvia ^a   Silverman, Earl D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ATHEROSCLEROSIS; BONE MASS; BONE NECROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHILD HEALTH CARE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; DYSLIPIDEMIA; ETHNIC DIFFERENCE; HEALTH STATUS; HEART PROTECTION; HUMAN; INJURY SEVERITY; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LUPUS ERYTHEMATOSUS NEPHRITIS; MUSCULOSKELETAL SYSTEM; NEUROPSYCHIATRY; ONSET AGE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UROGENITAL SYSTEM; VISUAL SYSTEM;

AGE OF ONSET; ATHEROSCLEROSIS; CHILD; COMORBIDITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OSTEOPOROSIS; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; SEX FACTORS; SURVIVAL RATE;

EID: 77956294432     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.121     Document Type: Review

References (124)

1. Ramirez Gomez, L. A. et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 17, 596-604 (2008).
2. Carreno, L. et al. immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 8, 287-292 (1999).
3. Font, J. et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann. Rheum. Dis. 57, 456-459 (1998).
4. Mok, C. C., Mak, A., Chu, w. P., To, C. H. & wong, S. N. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all agegroups. Medicine (Baltimore) 84, 218-224 (2005).
5. Lee, B. w. et al. A 10 year review of systemic lupus erythematosus in Singapore children. Aust. Paediatr. J. 23, 163-165 (1987).
6. Brunner, H. i., Silverman, E. D., To, T., Bombardier, C. & Feldman, B. M. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 46, 436-444 (2002).
7. Tucker, L. B., Menon, S., Schaller, J. G. & isenberg, D. A. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br. J. Rheumatol. 34, 866-872 (1995).
8. Hiraki, L. T. et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J. Pediatr. 152, 550-556 (2008).
9. Pluchinotta, F. R. et al. Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. Lupus 16, 550-555 (2007).
10. wong, S. N. et al. Lupus nephritis in Chinese children-a territory-wide cohort study in Hong Kong. Pediatr. Nephrol. 21, 1104-1112 (2006).
11. McCarty, D. J. et al. incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 38, 1260-1270 (1995).
12. Peschken, C. A. et al. The 1,000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J. Rheumatol. 36, 1200-1208 (2009).
13. Hiraki, L. T. et al. Ethnic differences in pediatric systemic lupus erythematosus. J. Rheumatol. 36, 2539-2546 (2009).
14. Cooper, G. S. et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 11, 161-167 (2002).
15. Huang, J. L., Yao, T. C. & See, L. C. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective population-based study in Taiwan. Clin. Exp. Rheumatol. 22, 776-780 (2004).
16. See, Y., Koh, E. T. & Boey, M. L. One hundred and seventy cases of childhood-onset rheumatological disease in Singapore. Ann. Acad. Med. Singapore 27, 496-502 (1998).
17. Yang, L. Y., Chen, w. P. & Lin, C. Y. Lupus nephritis in children-a review of 167 patients. Pediatrics 94, 335-340 (1994).
18. Tucker, L. B. et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case- control study within LUMiNA, a multiethnic US cohort (LUMiNA Lvii). Lupus 17, 314-322 (2008).
19. Hersh, A. O. et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 61, 13-20 (2009).
20. Pons-Estel, G. J., Alarcon, G. S., Scofield, L., Reinlib, L. & Cooper, G. S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 39, 257-268 (2009).
21. Huemer, C. et al. incidence of pediatric rheumatic diseases in a regional population in Austria. J. Rheumatol. 28, 2116-2119 (2001).
22. Denardo, B. A., Tucker, L. B., Miller, L. C., Szer, i. S. & Schaller, J. G. Demography of a regional pediatric rheumatology patient population. Affiliated Childrens Arthritis Centers of New England. J. Rheumatol. 21, 1553-1561 (1994).
23. Kaipiainen-Seppanen, O. & Savolainen, A. incidence of chronic juvenile rheumatic diseases in Finland during 1980-1990. Clin. Exp. Rheumatol. 14, 441-444 (1996).
24. Houghton, K. M., Page, J., Cabral, D. A., Petty, R. E. & Tucker, L. B. Systemic lupus erythematosus in the pediatric North American Native population of British Columbia. J. Rheumatol. 33, 161-163 (2006).
25. Malleson, P. N., Fung, M. Y. & Rosenberg, A. M. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J. Rheumatol. 23, 1981-1987 (1996).
26. Bahillo, M. P. et al. Incidence and prevalence of type 1 diabetes in children aged 15 yr in Castilla-Leon (Spain), Pediatr. Diabetes, 2007, 8, 369-373.
27. Janwityanujit, S., Totemchokchyakarn, K., verasertniyom, O., vanichapuntu, M. & vatanasuk, M. Age-related differences on clinical and immunological manifestations of SLE. Asian Pac. J. Allergy Immunol. 13, 145-149 (1995).
28. Brunner, H. i., Gladman, D. D., ibanez, D., Urowitz, M. D. & Silverman, E. D. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 58, 556-562 (2008).
29. Hoffman, i. E. et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann. Rheum. Dis. 68, 412-415 (2009).
30. Gutierrez-Suarez, R. et al. A proposal for a pediatric version of the Systemic Lupus international Collaborating Clinics/American College of Rheumatology Damage index based on the analysis of 1,015 patients with juvenileonset systemic lupus erythematosus. Arthritis Rheum. 54, 2989-2996 (2006).
31. Stoll, T., Stucki, G., Malik, J., Pyke, S. & isenberg, D. A. Association of the Systemic Lupus international Collaborating Clinics/American College of Rheumatology Damage index with measures of disease activity and health status in patients with systemic lupus erythematosus. J. Rheumatol. 24, 309-313 (1997).
32. Nossent, J. C. SLiCC/ACR Damage index in Afro- Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J. Rheumatol. 25, 654-659 (1998).
33. Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups. iX. Differences in damage accrual. Arthritis Rheum. 44, 2797-2806 (2001).
34. Swaak, A. J. et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) 38, 953-958 (1999).
35. Urowitz, M. B., Feletar, M., Bruce, i. N., ibanez, D. & Gladman, D. D. Prolonged remission in systemic lupus erythematosus. J. Rheumatol. 32, 1467-1472 (2005).
36. Candell Chalom, E. et al. Educational, vocational and socioeconomic status and quality of life in adults with childhood-onset systemic lupus erythematosus. Pediatr. Rheumatol. Online J. 2, 207-226 (2004).
37. Ravelli, A. et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum. 49, 501-507 (2003).
38. Bandeira, M. et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 15, 515-520 (2006).
39. Miettunen, P. M. et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J. Rheumatol. 31, 1650-1654 (2004).
40. Schanberg, L. E. et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum. 60, 1496-1507 (2009).
41. Gladman, D. et al. The development and initial validation of the Systemic Lupus international Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363-369 (1996).
42. Descloux, E. et al. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford) 47, 183-187 (2008).
43. Lilleby, v., Flato, B. & Forre, O. Disease duration, hypertension and medication requirements are associated with organ damage in childhoodonset systemic lupus erythematosus. Clin. Exp. Rheumatol. 23, 261-269 (2005).
44. Zonana-Nacach, A. et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 7, 119-123 (1998).
45. Sutcliffe, N., Stoll, T., Pyke, S. & isenberg, D. A. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjogrens syndrome (SS), and primary SS. J. Rheumatol. 25, 63-68 (1998).
46. Celermajer, D. S., Thorner, P. S., Baumal, R. & Arbus, G. S. Sex differences in childhood lupus nephritis. Am. J. Dis. Child. 138, 586-588 (1984).
47. Emre, S. et al. Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 87, 118-126 (2001).
48. Lee, B. S. et al. Clinical outcomes of childhood lupus nephritis: a single centers experience. Pediatr. Nephrol. 22, 222-231 (2007).
49. Hagelberg, S. et al. Longterm followup of childhood lupus nephritis. J. Rheumatol. 29, 2635-2642 (2002).
50. Pattaragarn, A. et al. Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients. J. Med. Assoc. Thai. 88 (Suppl. 8), S232-S241 (2005).
51. Al-Mayouf, S. M. & Al Sonbul, A. influence of gender and age of onset on the outcome in children with systemic lupus erythematosus. Clin. Rheumatol. 27, 1159-1162 (2008).
52. Bogdanovic, R. et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr. Nephrol. 19, 36-44 (2004).
53. Baqi, N. et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J. Am. Soc. Nephrol. 7, 924-929 (1996).
54. Lau, K. K., Jones, D. P., Hastings, M. C., Gaber, L. w. & Ault, B. H. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr. Nephrol. 21, 655-662 (2006).
55. Singh, S., Devidayal, Minz, R., Nada, R. & Joshi, K. Childhood lupus nephritis: 12 years experience from North india. Rheumatol. Int. 26, 604-607 (2006).
56. vachvanichsanong, P., Dissaneewate, P. & McNeil, E. Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood-onset lupus nephritis: a 23-year experience in a single centre. Nephrol. Dial. Transplant. 24, 2729-2734 (2009).
57. Hiraki, L. T., Hamilton, J. & Silverman, E. D. Measuring permanent damage in pediatric systemic lupus erythematosus. Lupus 16, 657-662 (2007).
58. Bjornadal, L., Yin, L., Granath, F., Klareskog, L. & Ekbom, A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-1995. J. Rheumatol. 31, 713-719 (2004).
59. ward, M. M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42, 338-346 (1999).
60. Asanuma, Y. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (2003).
61. Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408-415 (1997).
62. Pons-Estel, G. J. et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMiNA (LXviii), a multiethnic US cohort. Rheumatology (Oxford) 48, 817-822 (2009).
63. Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003).
64. Petri, M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9, 170-175 (2000).
65. Roman, M. J. et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 56, 3412-3419 (2007).
66. Toloza, S. M. et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMiNA). XXiii. Baseline predictors of vascular events. Arthritis Rheum. 50, 3947-3957 (2004).
67. Hahn, B. H. Systemic lupus erythematosus and accelerated atherosclerosis. N. Engl. J. Med. 349, 2379-2380 (2003).
68. Sandborg, C., Ardoin, S. P. & Schanberg, L. Therapy insight: cardiovascular disease in pediatric systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 4, 258-265 (2008).
69. Esdaile, J. M. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331-2337 (2001).
70. Ahmad, Y. et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 46, 983-988 (2007).
71. Tyrrell, P. N., Beyene, J., Benseler, S. M., Sarkissian, T. & Silverman, E. D. Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J. Rheumatol. 34, 2112-2119 (2007).
72. Doria, A. et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 62, 1071-1077 (2003).
73. Petri, M., Lakatta, C., Magder, L. & Goldman, D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med. 96, 254-259 (1994).
74. Sarkissian, T., Beyenne, J., Feldman, B., Adeli, K. & Silverman, E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum. 54, 1283-1290 (2006).
75. Lilleby, v. Bone status in juvenile systemic lupus erythematosus. Lupus 16, 580-586 (2007).
76. Sambrook, P. & Cooper, C. Osteoporosis. Lancet 367, 2010-2018 (2006).
77. Bailey, D. A., McKay, H. A., Mirwald, R. L., Crocker, P. R. & Faulkner, R. A. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J. Bone Miner. Res. 14, 1672-1679 (1999).
78. [No authors listed] Osteoporosis prevention, diagnosis, and therapy. NIH Consens. Statement 17 1-45 2000).
79. Trapani, S., Civinini, R., Ermini, M., Paci, E. & Falcini, F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol. Int. 18, 45-49 (1998).
80. Lilleby, v. et al. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum. 52, 2051-2059 (2005).
81. Lane, N. E. Therapy insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2, 562-569 (2006).
82. Alsufyani, K. A. et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J. Rheumatol. 32, 729-733 (2005).
83. Compeyrot-Lacassagne, S. et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 56, 1966-1973 (2007).
84. Regio, P., Bonfa, E., Takayama, L. & Pereira, R. The influence of lean mass in trabecular and cortical bone in juvenile onset systemic lupus erythematosus. Lupus 17, 787-792 (2008).
85. Baim, S. et al. Official Positions of the international Society for Clinical Densitometry and executive summary of the 2007 iSCD Position Development Conference. J. Clin. Densitom. 11, 75-91 (2008).
86. Castro, T. C. et al. Bone mineral density in juvenile systemic lupus erythematosus. Braz. J. Med. Biol. Res. 35, 1159-1163 (2002).
87. wang, M. C. et al. Diet in midpuberty and sedentary activity in prepuberty predict peak bone mass. Am. J. Clin. Nutr. 77, 495-503 (2003).
88. Greer, F. R. & Krebs, N. F. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 117, 578-585 (2006).
89. Specker, B. & Binkley, T. Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-year-old children. J. Bone Miner. Res. 18, 885-892 (2003).
90. Bachrach, L. K. & ward, L. M. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 94, 400-409 (2009).
91. Mok, C. C., Lau, C. S. & wong, R. w. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br. J. Rheumatol. 37, 895-900 (1998).
92. Assouline-Dayan, Y., Chang, C., Greenspan, A., Shoenfeld, Y. & Gershwin, M. E. Pathogenesis and natural history of osteonecrosis. Semin. Arthritis Rheum. 32, 94-124 (2002).
93. ibanez, D., Gladman, D. D. & Urowitz, M. B. Adjusted mean Systemic Lupus Erythematosus Disease Activity index-2K is a predictor of outcome in SLE. J. Rheumatol. 32, 824-827 (2005).
94. Campos, L. M., Kiss, M. H., DAmico, E. A. & Silva, C. A. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus 12, 820-826 (2003).
95. Castro, F. P. Jr, Hartz, R. S., Frigon, v. & whitecloud, T. S. 3rd. Aortic thrombosis after lumbar spine surgery. J. Spinal Disord. 13, 538-540 (2000).
96. Garberina, M. J., Berend, K. R., Gunneson, E. E. & Urbaniak, J. R. Results of free vascularized fibular grafting for femoral head osteonecrosis in patients with systemic lupus erythematosus. Orthop. Clin. North Am. 35, 353-357 (2004).
97. Strand, v. Lessons learned from clinical trials in SLE. Autoimmun. Rev. 6, 209-214 (2007).
98. Jolly, M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J. Rheumatol. 32, 1706-1708 (2005).
99. Falcini, F. & Nacci, F. Systemic lupus erythematosus in the young: the importance of a transition clinic. Lupus 16, 613-617 (2007).
100. wagner-weiner, L. Pediatric rheumatology for the adult rheumatologist. J. Clin. Rheumatol. 14, 109-119 (2008).
101. Lau, C. S. & Mak, A. The socioeconomic burden of SLE. Nat. Rev. Rheumatol. 5, 400-404 (2009).
102. Minden, K. et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 46, 2392-2401 (2002).
103. Peterson, L. S., Mason, T., Nelson, A. M., OFallon, w. M. & Gabriel, S. E. Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum. 40, 2235-2240 (1997).
104. McElhone, K., Abbott, J. & Teh, L. S. A review of health related quality of life in systemic lupus erythematosus. Lupus 15, 633-643 (2006).
105. Ruperto, N. et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Rheum. 51, 458-464 (2004).
106. Houghton, K. M., Tucker, L. B., Potts, J. E. & McKenzie, D. C. Fitness, fatigue, disease activity, and quality of life in pediatric lupus. Arthritis Rheum. 59, 537-545 (2008).
107. Moorthy, L. N. et al. Multicenter validation of a new quality of life measure in pediatric lupus. Arthritis Rheum. 57, 1165-1173 (2007).
108. Brunner, H. i. et al. Health-related quality of life and its relationship to patient disease course in childhood-onset systemic lupus erythematosus. J. Rheumatol. 36, 1536-1545 (2009).
109. Brunner, H. i. et al. Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting. Arthritis Rheum. 51, 763-773 (2004).
110. Moorthy, L. N. et al. Relationship between health-related quality of life and SLE activity and damage in children over time. Lupus 18, 622-629 (2009).
111. Ravelli, A., Ruperto, N. & Martini, A. Outcome in juvenile onset systemic lupus erythematosus. Curr. Opin. Rheumatol. 17, 568-573 (2005).
112. Appenzeller, S., Marini, R. & Costallat, L. T. Damage did not independently influence mortality in childhood systemic lupus erythematosus. Rheumatol. Int. 25, 619-624 (2005).
113. Singh, S., Devidayal, K. L. & Joshi, K. Mortality patterns in childhood lupus-10 years experience in a developing country. Clin. Rheumatol. 21, 462-465 (2002).
114. Olowu, w. Childhood-onset systemic lupus erythematosus. J. Natl Med. Assoc. 99, 777-784 (2007).
115. Uramoto, K. M. et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 42, 46-50 (1999).
116. Mok, C. C., Ho, C. T., wong, R. w. & Lau, C. S. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J. Rheumatol. 30, 1513-1519 (2003).
117. Pons-Estel, B. A. et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore) 83, 1-17 (2004).
118. Duran, S. et al. Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J. Natl Med. Assoc. 99, 1196-1198 (2007).
119. Danila, M. i. et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMiNA LXiv, a multiethnic US cohort. Rheumatology (Oxford) 48, 542-545 (2009).
120. ward, M. M., Pyun, E. & Studenski, S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum. 38, 274-283 (1995).
121. Kasitanon, N., Magder, L. S. & Petri, M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85, 147-156 (2006).
122. Manger, K. et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann. Rheum. Dis. 61, 1065-1070 (2002).
123. Urowitz, M. B., Gladman, D. D., Tom, B. D., ibanez, D. & Farewell, v. T. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J. Rheumatol. 35, 2152-2158 (2008).
124. Chambers, S. A., Allen, E., Rahman, A. & isenberg, D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48, 673-675 (2009).